<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12885">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939183</url>
  </required_header>
  <id_info>
    <org_study_id>20160104</org_study_id>
    <nct_id>NCT02939183</nct_id>
  </id_info>
  <brief_title>Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma</brief_title>
  <acronym>INTREPID-1</acronym>
  <official_title>(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in
      patients with relapsed refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, non-randomized, open-label, dose-exploration study evaluating two new
      formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed
      refractory multiple myeloma. The study will be conducted in two parts. Part 1 will evaluate
      the formulations of oprozomib in combination with dexamethasone only. Part 2 will evaluate
      the formulations of oprozomib administered at increasing dose levels (dose escalation) in
      combination with pomalidomide and dexamethasone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone</measure>
    <time_frame>The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib formulation 1 plus dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib formulation 2 plus dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib formulation 1 plus pomalidomide and dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib formulation 2 plus pomalidomide and dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oprozomib formulation 1</intervention_name>
    <description>Oprozomib formulation 1</description>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oprozomib formulation 2</intervention_name>
    <description>Oprozomib formulation 2</description>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide</description>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Subject must have a pathologically documented, definitively diagnosed, multiple
             myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy
             for multiple myeloma. Prior therapeutic treatment or regimens must include a
             proteasome inhibitor and lenalidomide.

          -  Subject must be willing and able to undergo bone marrow aspirate per protocol (with
             or without bone marrow biopsy per institutional guidelines).

          -  Measurable disease (assessed within 28 days prior to day 1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &gt;= 2.

          -  Other Inclusion Criteria May Apply

        Exclusion Criteria

          -  Currently receiving treatment in another investigational device or drug study, or
             less than 28 days since ending treatment on another investigational device or drug
             study.

          -  Previously received an allogeneic stem cell transplant and the occurrence of one or
             more of the following: received the transplant within 6 months prior to study day
             1;received immunosuppressive therapy within the last 3 months prior to study day
             1;having signs or symptoms of acute or chronic graft-versus-host disease.

          -  Autologous stem cell transplant &lt; 90 days prior to study day 1.

          -  Multiple myeloma with IgM subtype.

          -  POEMs syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes).

          -  Plasma cell leukemia (&gt; 2.0 X109/L circulating plasma cells by standard
             differential).

          -  Waldenstrom's macroglobulinemia.

          -  Other Exclusion Criteria May Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>October 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
